Log in

NASDAQ:BLFS - BioLife Solutions Stock Price, Forecast & News

+0.12 (+0.75 %)
(As of 12/9/2019 01:04 AM ET)
Today's Range
Now: $16.19
50-Day Range
MA: $16.54
52-Week Range
Now: $16.19
Volume93,001 shs
Average Volume180,307 shs
Market Capitalization$331.09 million
P/E Ratio115.64
Dividend YieldN/A
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:BLFS



Sales & Book Value

Annual Sales$19.74 million
Cash Flow$0.17 per share
Book Value$2.33 per share


Net Income$3.27 million


Market Cap$331.09 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.

BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

How were BioLife Solutions' earnings last quarter?

BioLife Solutions Inc (NASDAQ:BLFS) released its quarterly earnings data on Thursday, August, 9th. The medical equipment provider reported $0.05 EPS for the quarter, beating the consensus estimate of $0.04 by $0.01. The medical equipment provider had revenue of $5.18 million for the quarter, compared to analysts' expectations of $5.20 million. BioLife Solutions had a return on equity of 5.37% and a net margin of 46.77%. View BioLife Solutions' Earnings History.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for BioLife Solutions.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2020 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$50-56 million, compared to the consensus revenue estimate of $$42.95 million.

What price target have analysts set for BLFS?

5 equities research analysts have issued 12 month target prices for BioLife Solutions' shares. Their forecasts range from $5.00 to $26.00. On average, they expect BioLife Solutions' stock price to reach $19.60 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price. View Analyst Price Targets for BioLife Solutions.

What is the consensus analysts' recommendation for BioLife Solutions?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.

What are Wall Street analysts saying about BioLife Solutions stock?

Here are some recent quotes from research analysts about BioLife Solutions stock:
  • 1. According to Zacks Investment Research, "BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. " (11/25/2019)
  • 2. Maxim Group analysts commented, "On 5/9, BioLife reported 1Q19 with $5.8M in revenue, up 51% y/y and 6% sequentially, with a gross margin of 71.5%. BioLife also reported a $0.4M net profit for the quarter and ended the period with $31.8M in cash. We note that this does not include revenues from the Astero Acquisition (completed in April)." (5/22/2019)
  • 3. Northland Securities analysts commented, "We continue to believe BioLife is one of the better small-cap plays with a lower risk exposure to the biotech / regen med space. Maintain OP rating." (5/13/2019)

Has BioLife Solutions been receiving favorable news coverage?

Press coverage about BLFS stock has trended very negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioLife Solutions earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for BioLife Solutions.

Are investors shorting BioLife Solutions?

BioLife Solutions saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,980,000 shares, an increase of 5.3% from the October 31st total of 1,880,000 shares. Based on an average trading volume of 169,700 shares, the days-to-cover ratio is presently 11.7 days. Approximately 13.3% of the shares of the stock are short sold. View BioLife Solutions' Current Options Chain.

Who are some of BioLife Solutions' key competitors?

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Twilio (TWLO), NVIDIA (NVDA), AbbVie (ABBV), Square (SQ), Terra Tech (TRTC), Cara Therapeutics (CARA), Progenics Pharmaceuticals (PGNX), Verastem (VSTM) and Alibaba Group (BABA).

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the folowing people:
  • Mr. Michael P. Rice, Pres, CEO & Director (Age 56)
  • Mr. Roderick de Greef, CFO & Sec. (Age 59)
  • Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 47)
  • Ms. Karen Foster, VP of Operations (Age 59)
  • Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sandler Capital Management (3.07%), Russell Investments Group Ltd. (2.87%), Granahan Investment Management Inc. MA (1.32%), Essex Investment Management Co. LLC (0.99%), Cadence Capital Management LLC (0.91%) and State Street Corp (0.64%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.

Which institutional investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sandler Capital Management, Roubaix Capital LLC, Essex Investment Management Co. LLC, Ancora Advisors LLC, Cadence Capital Management LLC, Barclays PLC and Janney Montgomery Scott LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Todd Berard and Walter Villiger. View Insider Buying and Selling for BioLife Solutions.

Which institutional investors are buying BioLife Solutions stock?

BLFS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Granahan Investment Management Inc. MA, Perkins Capital Management Inc., State Street Corp and Alpine Woods Capital Investors LLC. View Insider Buying and Selling for BioLife Solutions.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $16.19.

How big of a company is BioLife Solutions?

BioLife Solutions has a market capitalization of $331.09 million and generates $19.74 million in revenue each year. The medical equipment provider earns $3.27 million in net income (profit) each year or $0.14 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.View Additional Information About BioLife Solutions.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is http://www.biolifesolutions.com/.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]

MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: What causes a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel